Skip to main content
Fig. 4 | Cancer Nanotechnology

Fig. 4

From: Non-small cell lung cancer targeted nanoparticles with reduced side effects fabricated by flash nanoprecipitation

Fig. 4

Biodistribution of gefitinib in vivo. a Normalized concentrations of gefitinib in plasma (in FA-NPs or free form); b tissue distributions of gefitinib in HCC827-tumor-bearing nude mice after intravenous injection of FA-NPs or free gefitinib for designed time intervals. *P < 0.05 and **P < 0.01, compared between the indicated groups

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us